Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10534821rdf:typepubmed:Citationlld:pubmed
pubmed-article:10534821lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:10534821lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:10534821lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:10534821lifeskim:mentionsumls-concept:C0444706lld:lifeskim
pubmed-article:10534821lifeskim:mentionsumls-concept:C2587213lld:lifeskim
pubmed-article:10534821lifeskim:mentionsumls-concept:C0010174lld:lifeskim
pubmed-article:10534821pubmed:dateCreated1999-11-4lld:pubmed
pubmed-article:10534821pubmed:abstractTextA randomized controlled trial of the costs and benefits of teledermatology consultations compared with traditional hospital consultations was carried out. Over a nine-month period, 197 patients were referred from general practice for a dermatological opinion, 98 for a teledermatology consultation and 99 for a hospital consultation. Eighty patients required an additional subsequent hospital appointment. Patients were asked to complete an economic questionnaire after each consultation, and 164 questionnaires were returned: 62% of those randomized to the teledermatology consultation responded compared with 58% of those randomized to the hospital consultation. Patients seen by teledermatology at their own health centre had shorter distances to travel and spent less time overall attending the appointment compared with those seen at the hospital. However, the teledermatology consultations were more time-consuming for the general practitioner and dermatologist. These findings indicate that teledermatology has more benefits for the patient than for the health-care delivery team.lld:pubmed
pubmed-article:10534821pubmed:languageenglld:pubmed
pubmed-article:10534821pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10534821pubmed:citationSubsetIMlld:pubmed
pubmed-article:10534821pubmed:statusMEDLINElld:pubmed
pubmed-article:10534821pubmed:issn1357-633Xlld:pubmed
pubmed-article:10534821pubmed:authorpubmed-author:MathewsCClld:pubmed
pubmed-article:10534821pubmed:authorpubmed-author:WoottonRRlld:pubmed
pubmed-article:10534821pubmed:authorpubmed-author:CorbettRRlld:pubmed
pubmed-article:10534821pubmed:authorpubmed-author:SteeleKKlld:pubmed
pubmed-article:10534821pubmed:authorpubmed-author:HicksNNlld:pubmed
pubmed-article:10534821pubmed:authorpubmed-author:PaisleyJJlld:pubmed
pubmed-article:10534821pubmed:authorpubmed-author:EedyD JDJlld:pubmed
pubmed-article:10534821pubmed:authorpubmed-author:LoaneM AMAlld:pubmed
pubmed-article:10534821pubmed:authorpubmed-author:GoreH EHElld:pubmed
pubmed-article:10534821pubmed:authorpubmed-author:BloomerS ESElld:pubmed
pubmed-article:10534821pubmed:issnTypePrintlld:pubmed
pubmed-article:10534821pubmed:volume5 Suppl 1lld:pubmed
pubmed-article:10534821pubmed:ownerNLMlld:pubmed
pubmed-article:10534821pubmed:authorsCompleteYlld:pubmed
pubmed-article:10534821pubmed:paginationS1-3lld:pubmed
pubmed-article:10534821pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10534821pubmed:meshHeadingpubmed-meshheading:10534821...lld:pubmed
pubmed-article:10534821pubmed:meshHeadingpubmed-meshheading:10534821...lld:pubmed
pubmed-article:10534821pubmed:meshHeadingpubmed-meshheading:10534821...lld:pubmed
pubmed-article:10534821pubmed:meshHeadingpubmed-meshheading:10534821...lld:pubmed
pubmed-article:10534821pubmed:meshHeadingpubmed-meshheading:10534821...lld:pubmed
pubmed-article:10534821pubmed:meshHeadingpubmed-meshheading:10534821...lld:pubmed
pubmed-article:10534821pubmed:meshHeadingpubmed-meshheading:10534821...lld:pubmed
pubmed-article:10534821pubmed:meshHeadingpubmed-meshheading:10534821...lld:pubmed
pubmed-article:10534821pubmed:meshHeadingpubmed-meshheading:10534821...lld:pubmed
pubmed-article:10534821pubmed:meshHeadingpubmed-meshheading:10534821...lld:pubmed
pubmed-article:10534821pubmed:meshHeadingpubmed-meshheading:10534821...lld:pubmed
pubmed-article:10534821pubmed:meshHeadingpubmed-meshheading:10534821...lld:pubmed
pubmed-article:10534821pubmed:meshHeadingpubmed-meshheading:10534821...lld:pubmed
pubmed-article:10534821pubmed:meshHeadingpubmed-meshheading:10534821...lld:pubmed
pubmed-article:10534821pubmed:meshHeadingpubmed-meshheading:10534821...lld:pubmed
pubmed-article:10534821pubmed:meshHeadingpubmed-meshheading:10534821...lld:pubmed
pubmed-article:10534821pubmed:meshHeadingpubmed-meshheading:10534821...lld:pubmed
pubmed-article:10534821pubmed:year1999lld:pubmed
pubmed-article:10534821pubmed:articleTitlePatient cost-benefit analysis of teledermatology measured in a randomized control trial.lld:pubmed
pubmed-article:10534821pubmed:affiliationInstitute of Telemedicine and Telecare, Royal Group of Hospitals, Belfast, UK. m.loane@qub.ac.uklld:pubmed
pubmed-article:10534821pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10534821pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:10534821pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:10534821pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:10534821pubmed:publicationTypeMulticenter Studylld:pubmed